CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytomX Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.34+0.06 (+2.63%)
Close on Oct 19, 2026
- Market cap
- $512.32M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
97.9%
213M of 218M shares
Institutional holders
179
47 new, 45 sold out
Net institutional buying
20M
In Q2 2026
Insider trades, 12 months
0 buys · 6 sales
Net sold $1.69M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | 9,680,185 | 5.90% | 13G (passive) | Aug 14, 2025 |
| Kevin Tang | 6,550,000 | 9.80% | 13G (passive) amendment | Dec 31, 2023 |
| Abigail P. Johnson | 24,688,109 | 14.60% | 13G (passive) amendment | Dec 31, 2025 |
| FMR LLC | 20,519,967 | 12.40% | 13G (passive) amendment | Oct 31, 2025 |
| BlackRock, Inc. | 16,551,452 | 7.60% | 13G (passive) | Jun 30, 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 15,561,500 | 9.40% | 13G (passive) amendment | Sep 30, 2025 |
| Juliet Tammenoms Bakker | 15,288,461 | 7.00% | 13G (passive) amendment | Mar 31, 2026 |
| Bank Of America Corp /De/ | 15,134,689 | 7.00% | 13G (passive) | Jun 30, 2026 |
| VHCP Management III, LLC | 12,992,500 | 8.20% | 13G (passive) | May 13, 2025 |
| State Street Corporation | 11,747,236 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Lampert Mark N | 11,538,462 | 6.80% | 13G (passive) amendment | Jun 30, 2025 |
| Longitude Venture Partners V, L.P. | 11,538,461 | 7.30% | 13G (passive) | May 13, 2025 |
| Point72 Capital Advisors, Inc. | 10,864,581 | 5.00% | 13G (passive) | Apr 15, 2026 |
| Kynam Capital Management GP, LLC | 0 | 6.90% | 13G (passive) amendment | Mar 31, 2026 |
| Yue Tang | 0 | 9.96% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CTMX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 32,714,937 | 15.01% | $122.68M | +759,300 | 0.01% |
| Kynam Capital Management, LP | 21,703,093 | 9.96% | $81.39M | +6,690,000 | 4.50% |
| BlackRock, Inc. | 17,559,822 | 8.06% | $65.85M | +12,331,542 | 0.00% |
| Bank Of America Corp /De/ | 15,082,617 | 6.92% | $56.56M | +4,879,832 | 0.00% |
| State Street Corp | 11,747,236 | 5.39% | $44.05M | +6,083,828 | 0.00% |
| Perceptive Advisors LLC | 10,439,185 | 4.79% | $39.15M | +340,361 | 0.59% |
| Vanguard Capital Management LLC | 8,525,457 | 3.91% | $31.97M | −207,661 | 0.00% |
| Point72 Asset Management, L.P. | 7,811,033 | 3.58% | $29.29M | −64,357 | 0.03% |
| Wellington Management Group Llp | 5,168,961 | 2.37% | $19.38M | +1,585,976 | 0.00% |
| VR Adviser, LLC | 4,982,124 | 2.29% | $18.68M | −5,000,000 | 0.57% |
| Baker Bros. Advisors LP | 4,975,826 | 2.28% | $18.66M | – | 0.09% |
| Geode Capital Management, LLC | 4,678,716 | 2.15% | $17.55M | +2,612,104 | 0.00% |
| Elmind Capital, LP | 4,550,000 | 2.09% | $17.06M | – | 4.29% |
| Nextech Invest, Ltd. | 4,449,932 | 2.04% | $16.69M | – | 0.79% |
| Two Sigma Investments, LP | 4,132,643 | 1.90% | $15.50M | +1,422,487 | 0.01% |
| Eversept Partners, LP | 3,558,497 | 1.63% | $13.34M | +369,983 | 0.69% |
| UBS Group AG | 3,468,359 | 1.59% | $13.01M | +348,204 | 0.00% |
| Siren, L.L.C. | 3,457,711 | 1.59% | $12.97M | – | 0.26% |
| ADAR1 Capital Management, LLC | 3,365,118 | 1.54% | $12.62M | −45,072 | 0.58% |
| Citadel Advisors LLC | 3,110,509 | 1.43% | $11.66M | −2,295,684 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 179 | 213M | 97.9% | 47 / 72 | 33 / 45 | 49M | 29M |
| Q1 2026 | 179 | 193M | 88.7% | 77 / 59 | 28 / 19 | 94M | 37M |
| Q4 2025 | 122 | 144M | 66.1% | 39 / 38 | 26 / 20 | 38M | 32M |
| Q3 2025 | 103 | 137M | 63.1% | 32 / 29 | 25 / 12 | 31M | 27M |
| Q2 2025 | 83 | 134M | 61.3% | 29 / 27 | 17 / 12 | 104M | 15M |
| Q1 2025 | 66 | 45M | 20.8% | 7 / 20 | 26 / 11 | 5M | 6M |
| Q4 2024 | 70 | 47M | 21.4% | 12 / 24 | 21 / 10 | 7M | 12M |
| Q3 2024 | 69 | 51M | 23.5% | 10 / 18 | 23 / 13 | 8M | 6M |
| Q2 2024 | 74 | 51M | 23.3% | 13 / 29 | 24 / 27 | 18M | 13M |
| Q1 2024 | 88 | 46M | 21.2% | 28 / 19 | 24 / 8 | 16M | 2M |
| Q4 2023 | 68 | 33M | 15.0% | 9 / 16 | 20 / 3 | 1M | 1M |
| Q3 2023 | 62 | 32M | 14.9% | 3 / 11 | 25 / 8 | 1M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CTMX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,964,209 | 3.65% | $29.87M | 0.28% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 6,230,387 | 2.86% | $23.36M | 0.00% | Jun 30, 2026 |
| Select Health Care Portfolio | 5,000,000 | 2.29% | $18.00M | 0.31% | May 31, 2026 |
| iShares Russell 2000 ETF | 4,607,592 | 2.11% | $17.28M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 3,970,290 | 1.82% | $12.31M | 0.14% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 2,774,340 | 1.27% | $9.99M | 0.19% | May 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 2,652,100 | 1.22% | $9.55M | 0.00% | May 31, 2026 |
| Fidelity Advisor Health Care Fund | 2,500,000 | 1.15% | $7.75M | 0.25% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 2,490,551 | 1.14% | $7.72M | 0.35% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 2,450,510 | 1.12% | $7.60M | 0.10% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 2,096,625 | 0.96% | $7.86M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Growth K6 Fund | 1,988,030 | 0.91% | $6.16M | 0.13% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 1,947,498 | 0.89% | $6.04M | 0.02% | Jul 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 1,736,495 | 0.80% | $5.38M | 0.11% | Jul 31, 2026 |
| Fidelity U.S. Equity Central Fund | 1,420,000 | 0.65% | $5.33M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sean A. McCarthy | CEO, Director | 2,253,129 | 1.03% | Mar 19, 2026 |
| Alejandra Carvajal | Chief Legal Officer | 100,000 | 0.05% | Aug 5, 2026 |
| Christopher Ogden | Chief Financial Officer | 295,324 | 0.14% | Jun 17, 2026 |
| Marcia Belvin | SVP, Chief Scientific Officer | 300,760 | 0.14% | Mar 19, 2026 |
| Yu-Waye Chu | Chief Medical Officer | 189,446 | 0.09% | Mar 19, 2026 |
| Rachael Lester | Chief Business Officer | 20,000 | 0.01% | Feb 4, 2026 |
| Lloyd A. Rowland | General Counsel | 120,594 | 0.06% | Mar 20, 2025 |
| Charles S. Fuchs | Director | – | – | Jul 30, 2026 |
| Halley E. Gilbert | Director | – | – | Jun 22, 2026 |
| Matthew P. Young | Director | – | – | Jun 22, 2026 |
| Alan Ashworth | Director | – | – | Jun 22, 2026 |
| James R. Meyers | Director | – | – | Jun 22, 2026 |
| Elaine V. Jones | Director | 5,142 | 0.00% | Jun 22, 2026 |
| Zhen Su | Director | – | – | Jun 22, 2026 |
| Mani Mohindru | Director | – | – | Jun 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alejandra Carvajal Chief Legal Officer | Aug 3, 2026 | Award | +100,000 | – | – | 100,000 |
| Christopher Ogden Chief Financial Officer | Jun 15, 2026 | Sale | −1,624 | $3.05 | $4.95K | 295,324 |
| Christopher Ogden Chief Financial Officer | Mar 17, 2026 | Sale | −19,323 | $6.42 | $124.05K | 296,948 |
| Sean A. McCarthy CEO, Director | Mar 17, 2026 | Sale(10b5-1 plan) | −118,969 | $6.42 | $763.78K | 1,078,922 |
| Marcia Belvin SVP, Chief Scientific Officer | Mar 17, 2026 | Sale | −31,492 | $6.42 | $202.18K | 300,760 |
| Yu-Waye Chu Chief Medical Officer | Mar 17, 2026 | Sale | −21,279 | $6.42 | $136.61K | 189,446 |
| Sean A. McCarthy CEO, Director | Feb 2, 2026 | Award | +210,000 | – | – | 1,197,891 |
| Yu-Waye Chu Chief Medical Officer | Feb 2, 2026 | Award | +75,000 | – | – | 210,725 |
| Marcia Belvin SVP, Chief Scientific Officer | Feb 2, 2026 | Award | +60,000 | – | – | 332,252 |
| Christopher Ogden Chief Financial Officer | Feb 2, 2026 | Award | +90,000 | – | – | 316,271 |
| Rachael Lester Chief Business Officer | Feb 2, 2026 | Award | +20,000 | – | – | 20,000 |
| Sean A. McCarthy CEO, Director | Nov 6, 2025 | Sale(10b5-1 plan) | −101,793 | $4.54 | $462.14K | 987,891 |
| Marcia Belvin SVP, Chief Scientific Officer | Jun 16, 2025 | Sale | −13,884 | $2.69 | $37.35K | 272,252 |
| Christopher Ogden Chief Financial Officer | Jun 16, 2025 | Sale | −10,614 | $2.69 | $28.55K | 226,271 |
| Sean A. McCarthy CEO, Director | Jun 16, 2025 | Sale | −55,511 | $2.69 | $149.32K | 1,089,684 |
| Marcia Belvin SVP, Chief Scientific Officer | Jun 13, 2025 | Option exercise | +37,500 | – | – | 286,136 |
| Christopher Ogden Chief Financial Officer | Jun 13, 2025 | Sale | −1,641 | $2.95 | $4.84K | 199,385 |
| Christopher Ogden Chief Financial Officer | Jun 13, 2025 | Option exercise | +37,500 | – | – | 236,885 |
| Sean A. McCarthy CEO, Director | Jun 13, 2025 | Option exercise | +150,000 | – | – | 1,145,195 |
| Christopher Ogden Chief Financial Officer | Mar 18, 2025 | Sale | −8,551 | $0.60 | $5.13K | 201,026 |
| Marcia Belvin SVP, Chief Scientific Officer | Mar 18, 2025 | Sale | −19,512 | $0.60 | $11.71K | 248,636 |
| Sean A. McCarthy CEO, Director | Mar 18, 2025 | Sale | −37,656 | $0.60 | $22.59K | 995,195 |
| Yu-Waye Chu Chief Medical Officer | Mar 18, 2025 | Sale | −4,025 | $0.60 | $2.42K | 135,725 |
| Lloyd A. Rowland General Counsel | Mar 18, 2025 | Sale | −10,203 | $0.60 | $6.12K | 120,594 |
| Marcia Belvin SVP, Chief Scientific Officer | Feb 4, 2025 | Award | +35,000 | – | – | 210,648 |
| Marcia Belvin SVP, Chief Scientific Officer | Feb 4, 2025 | Award | +57,500 | – | – | 268,148 |
| Yu-Waye Chu Chief Medical Officer | Feb 4, 2025 | Award | +56,000 | – | – | 82,250 |
| Yu-Waye Chu Chief Medical Officer | Feb 4, 2025 | Award | +57,500 | – | – | 139,750 |
| Sean A. McCarthy CEO, Director | Feb 4, 2025 | Award | +180,000 | – | – | 837,851 |
| Sean A. McCarthy CEO, Director | Feb 4, 2025 | Award | +195,000 | – | – | 1,032,851 |
| Christopher Ogden Chief Financial Officer | Feb 4, 2025 | Award | +57,500 | – | – | 209,577 |
| Christopher Ogden Chief Financial Officer | Feb 4, 2025 | Award | +44,000 | – | – | 152,077 |
| Marcia Belvin SVP, Chief Scientific Officer | Feb 4, 2025 | Award | +57,500 | – | – | 263,148 |
| Marcia Belvin SVP, Chief Scientific Officer | Feb 4, 2025 | Award | +30,000 | – | – | 205,648 |
| Christopher Ogden Chief Financial Officer | Aug 20, 2024 | Sale | −1,984 | $1.23 | $2.44K | 108,077 |
| Christopher Ogden Chief Financial Officer | Aug 20, 2024 | Option exercise | +6,875 | – | – | 110,061 |
| Jeffrey B. Landau Chief Business Officer | Aug 20, 2024 | Sale | −4,181 | $1.23 | $5.14K | 119,056 |
| Jeffrey B. Landau Chief Business Officer | Aug 20, 2024 | Option exercise | +11,250 | – | – | 123,237 |
| Marcia Belvin SVP, Chief Scientific Officer | Aug 20, 2024 | Sale | −4,181 | $1.23 | $5.14K | 175,648 |
| Marcia Belvin SVP, Chief Scientific Officer | Aug 20, 2024 | Option exercise | +11,250 | – | – | 179,829 |
| Sean A. McCarthy CEO, Director | Aug 20, 2024 | Option exercise | +37,500 | – | – | 671,749 |
| Sean A. McCarthy CEO, Director | Aug 20, 2024 | Sale | −13,898 | $1.23 | $17.09K | 657,851 |
| Lloyd A. Rowland General Counsel | Aug 20, 2024 | Sale | −4,181 | $1.23 | $5.14K | 130,797 |
| Lloyd A. Rowland General Counsel | Aug 20, 2024 | Option exercise | +11,250 | – | – | 134,978 |
| Christopher Ogden Chief Financial Officer | Jun 12, 2024 | Award | +17,500 | – | – | 103,186 |
| Sean A. McCarthy CEO, Director | Mar 26, 2024 | Option exercise | +109,768 | $1.57 | $172.34K | 634,249 |
| Christopher Ogden SVP, Finance and Accounting | Mar 19, 2024 | Sale | −2,971 | $2.09 | $6.21K | 85,686 |
| Lloyd A. Rowland General Counsel | Mar 19, 2024 | Sale | −5,268 | $2.09 | $11.01K | 117,728 |
| Sean A. McCarthy CEO, Director | Mar 19, 2024 | Sale | −20,223 | $2.09 | $42.27K | 524,481 |
| Marcia Belvin SVP, Chief Scientific Officer | Mar 19, 2024 | Sale | −12,795 | $2.09 | $26.74K | 168,579 |
| Jeffrey B. Landau Chief Business Officer | Mar 19, 2024 | Sale | −6,562 | $2.09 | $13.71K | 110,060 |
| Sean A. McCarthy CEO, Director | Jan 18, 2024 | Award | +90,000 | – | – | 544,704 |
| Yu-Waye Chu Chief Medical Officer | Jan 18, 2024 | Award | +26,250 | – | – | 26,250 |
| Marcia Belvin SVP, Chief Scientific Officer | Jan 18, 2024 | Award | +26,250 | – | – | 181,374 |
| Jeffrey B. Landau Chief Business Officer | Jan 18, 2024 | Award | +30,000 | – | – | 116,622 |
| Christopher Ogden SVP, Finance and Accounting | Jan 18, 2024 | Award | +40,000 | – | – | 88,657 |
| Lloyd A. Rowland General Counsel | Jan 18, 2024 | Award | +25,000 | – | – | 122,996 |
| Christopher Ogden SVP, Finance and Accounting | Dec 20, 2023 | Sale | −1,990 | $1.38 | $2.75K | 48,657 |
| Jeffrey B. Landau Chief Business Officer | Dec 20, 2023 | Sale | −4,077 | $1.38 | $5.63K | 86,622 |
| Lloyd A. Rowland General Counsel | Dec 20, 2023 | Sale | −4,077 | $1.38 | $5.63K | 97,996 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| McCarthy Sean CEO | Nov 6, 2025 | 101,793 | $461.91K | Nov 6, 2025 | Stock Option |